This is a study of the sodium channel inhibitor, GSK2339345. Cohort 1 will assess the safety,
tolerability and PK of single ascending doses of GSK2339345 administered via an aqueous
droplet inhaler in healthy subjects. Cohort 2 will assess the safety, tolerability, and PK of
repeat doses of GSK2339345 administered four times a day for two consecutive days via an
aqueous droplet inhaler.